Stock · SYK · Healthcare
United States · Large Cap · listed since 1988 · Revenue 12 mo. $25.8B
Price as of 11/06/2026
Stryker Corporation operates as a medical technology company in the United States and internationally.
Stryker Corporation operates as a medical technology company in the United States and internationally. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, patient and caregiver safety technologies, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism; traditional brain and open skull based surgical procedures products; and orthobiologic and biosurgery products, including synthetic bone grafts and vertebral augmentation products. The Orthopaedics segment provides implants for use in total joint replacements, such as hip, knee and shoulder, ankle, and trauma and extremities surgeries; and Mako Shoulder, which expands the smart robotics suite of applications. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 61 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
Original text from the data provider
Summary
44.9 of 100
Mean of the six area values. Each area value is the mean of the stock's ranks among the companies in its sector. 50 is the middle of the sector, not a share of companies beaten.
Analysis
What the price requires
If free cash flow stays at €3.8B (2025), it supports €42.7B. The remaining €63.2B of the market value assume it grows 12.7% a year for 10 years and not at all afterwards.
Required FCF growth per year
12.7%
no growth afterwards
Price to operating cash flow 22.8×, below its usual range.
Middle half of 20 quarters: 29.3× to 35.8×, median 32.4×.
Measures only against its own past, not against what the company is worth. Price as of 11/06/2026.
with respect to the priced-in expectation
with respect to the priced-in expectation
No anomaly in the stored figures.
Since the last quarter
Q1 → Q2 2026
7 more unchanged: Revenue, 12 mo., FCF, 12 mo., Gross margin, FCF margin, Net debt, Shares outstanding, Return on equity
Derivation
Each area value is the average of its metrics' ranks within the sector (0 to 100, 50 is the middle). For metrics where lower is better, the rank is mirrored. The overall value is the average of the area values.
Price as of 11/06/2026.
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Return on equity | 14.48% | 11.52% | Rank 64 |
| Return on capital (Greenblatt) | 43.05% | 32.55% | Rank 64 |
| EBIT margin | 19.47% | 18.31% | Rank 56 |
| FCF margin | 17.05% | 14.12% | Rank 61 |
| Gross margin | 63.96% | 60.99% | Rank 52 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Revenue growth, 1 year | 11.16% | 8.04% | Rank 67 |
| Earnings growth, 3 years per year | 11.24% | 5.44% | Rank 62 |
| Earnings growth, 5 years per year | 15.10% | 7.00% | Rank 71 |
| Sustainable growth (ROE × retained earnings) | 3.03% | 3.66% | Rank 39 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Earnings yield | 2.61% | 2.90% | Rank 41 |
| FCF yield | 3.63% | 3.63% | Rank 50 |
| EV/saleslower is better | 5.19 | 4.03 | Rank 39 |
| EV/EBITlower is better | 26.65 | 21.73 | Rank 38 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Share price, 1 year | −17.50% | 8.66% | Rank 21 |
| Share price, 6 months | 14.64% | 24.27% | Rank 37 |
| Share price, 3 months | 1.25% | 15.42% | Rank 16 |
| Distance from 52-week high | −15.90% | −7.35% | Rank 26 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Accruals (Sloan)lower is better | 6.76% | 0.30% | Rank 15 |
| Change in share countlower is better | −0.88% | 0.00% | Rank 66 |
| Dividend streak in years | 16 | 10 | Rank 76 |
| Price reaction to results, market-adjusted | −4.78% | 0.05% | Rank 14 |
| Metric | Stock | Sector median | Position in sector |
|---|---|---|---|
| Equity ratio | 46.86% | 48.40% | Rank 45 |
| Net debt/EBITDAlower is better | 1.94 | 1.11 | Rank 31 |
| Debt to equitylower is better | 0.73 | 0.48 | Rank 37 |
| Volatility, 1 yearlower is better | 31.42% | 31.42% | Rank 50 |
Ten years in figures
| Year | Revenue, $B | EBIT margin | FCF | Shares | Net debt, $B |
|---|---|---|---|---|---|
| 2016 | 11.3 | 22.8% | $1.4B | 379M | 3.4 |
| 2017 | 12.4 | 22.2% | $961.0M | 380M | 4.0 |
| 2018 | 13.6 | 22.8% | $2.0B | 380M | 4.9 |
| 2019 | 14.9 | 22.8% | $1.5B | 380M | 5.9 |
| 2020 | 14.4 | 21.1% | $2.8B | 380M | 10.3 |
| 2021 | 17.1 | 22.0% | $2.7B | 382M | 9.5 |
| 2022 | 18.4 | 20.2% | $2.0B | 382M | 11.7 |
| 2023 | 20.5 | 20.9% | $3.1B | 384M | 10.5 |
| 2024 | 22.6 | 16.3% | $3.5B | 386M | 9.9 |
| 2025 | 25.1 | 19.5% | $4.3B | 382M | 12.3 |
3 of 7 StockScorer Score rules met · How the score is built
Stryker Corporation mainly meets criteria in the Profitability category. Result from 18 strategies checked.
Stryker Corporation is rated here with the StockScorer Score strategy, the flagship rule set. It compares return and cash-flow metrics with the median of the company's own sector and checks growth and price trend.
3 of 7 rules met
5 of 11 points
Detail data
Excerpt from 18 strategies checked. The full evaluation is visible after a free sign-up.
With a free account, you can see the match across all strategies checked in one complete overview.
Selected fundamental metrics for Stryker Corporation.
| Metric | Stock | Sector |
|---|---|---|
| P/E ratio | 38.4 | 30.0 |
| P/B ratio | 5.6 | 4.8 |
| Return on equity (ROE) | 14.5% | 11.5% |
| Equity ratio | 46.9% | 48.4% |
| Debt-to-equity (D/E) | 0.73 | 0.48 |
| Dividend yield | 1.1% | 1.3% |
How comparable stocks in the same sector score in the StockScorer model.
| Symbol | Company | Rating |
|---|---|---|
| SYK | Stryker Corporationthis page | |
| BSX | Boston Scientific Corp | High9.1 |
| EW | Edwards Lifesciences Corp | Low1.8 |
| ABT | Abbott Laboratories | High6.4 |
| GEHC | GE HealthCare Technologies Inc. | locked |
| MDT | Medtronic PLC | locked |
Signed up in 30 seconds, free.
Learn more about the metrics in the metrics glossary or all rated stocks in the stock overview.
How StockScorer rates every stock is explained on the methodology page.